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ABSTRACT 
 
From September 1984 to August 1991, 48 evaluable patients with resected gastric 
cancer and apparent disease confined to locoregional area were treated with 
intraoperative electron beam boost to the celiac axis and peripancreatic nodal areas (15 
Gy) and external irradiation (40 to 46 Gy in 4 to 5 weeks ) including the gastric bed and 
upper abdominal nodal draining regions. At the time of evaluation for IORT, the disease 
was primary in 38 cases, recurrent but resectable in four (anastomosis), and unresectable 
in four (nodal). Post operative complications were reversible. Acute tolerance to the 
complete treatment program was acceptable. Late complications included life-
threatening events: Six episodes of gastro intestinal bleeding (three of them had an 
arteriographic documentation of arterioenteric fistula) and nine with severe enteritis 
(five required reoperation). Other long-term treatment related complications were six 
cases of vertebral collapse. The median follow-up time for the entire group is 22 
months. Locoregional recurrence / persistence of disease has been identified in five 
patients (three with residual and /or recurrent postsurgical tumor). Systemic tumor 
progression has been detected in 15 patients (11 in intra-abdominal sites). Overall 
actuarial survival for patients with positive or negative serosal involvement was 33% 
versus 56%. It is concluded that the treatment program described is able to induce a 
high locoregional tumor control rate (100%) when used strictly in an adjuvant setting 
and might control long term, a small portion of patients not amenable for curative 
surgery (2 out of 8 patients with confirmed residual post-surgical disease). 
Gastrointestinal bleeding and enteritis are findings that indicate treatment intensity at 
the upper limits of tissue tolerance. Assessment of long term tolerance of pancreatic 
parenchima and large blood vessels (tissues included in the IRORT field) are pending 
for longer follow-up and the appropriate selective studies. 
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INTRODUCTION 
 
Studies analyzing the patterns of tumor recurrence following surgery for gastric cancer 
have consistently shown a certain tendency to develop involvement of locoregional 
areas. Reports of autopsy studies (46), planned reoperation series (23) and retrospective 
reviews (38) identified the gastric bed, nodal regions, duodenal or anastomosis stump as 
the locoregional areas and structures with higher risk of tumor relapse. The locoregional 
recurrence rate is estimated in excess of 35% for those patients with serosal and/ or 
nodal involvement (30). 
 
Radiotherapy as a locoregional adjuvant treatment modality has been pursued in 
multidisciplinary protocols (15, 28, 44). The limited tolerance of upper abdominal 
organs and tissue structures (22, 37), and the complexity to define the target volume for 
adequate postoperative radiotherapy in gastric cancer patients, are some of the critical 
issues to consider for the integration of radiotherapy in multimodal approaches (16, 21). 
 
Intraoperative radiotherapy (IORT) is a treatment modality able to deliver accurately a 
high dose of radiation to upper abdominal areas, while protecting some normal tissues 
(2). IORT has been successfully used in the treatment of gastric cancer patients (1, 3). 
External beam radiotherapy techniques for post-gastrectomy patients have been refined 
in the last decade (31). The combination of an IORT boost to a large external irradiation 
volume constitutes an intense locoreginal treatment program, particularly attractive to 
be tested in patients with initially localized and resectable gastric cancer. This study 
analyzes the results obtained in a clinical trial using the combination surgery with or 
without gastrectomy (isolated recurrences were accepted for the trial), IORT and 
external beam irradiation. The preliminary findings were previously reported in an 
earlier description of technical features and clinical results analysis (12). 
 
 
 
METHODS AND MATERIALS 
 
From September 1984 to August 1991, 56 patients with gastric neoplasms entered in a 
Phase oriented clinical therapeutic trial combining gastrectomy, IORT (15 Gy) and 
external beam irradiation (46 Gy in 5 weeks). Eight patients were excluded for this 
analysis: four had metastatic disease outside the IORT field (one liver, one peritoneal, 
two positive peritoneal cytology), three had histologies other than adenocarcinoma (two 
lymphomas and 1 leiomyosarcoma) and one patient was lost to follow-up early after the 
initial treatment. 
 
The treatment protocol and technical aspects have been described in detail in a previous 
report (12). In summary, patients with localized gastric adenocarcinoma were 
approached by gastrectomy, nodal sampling, IORT electron boost to the celiac axis and 
pancreatic nodes (15 Gy) (Fig. 1), and external beam irradiation to a large upper 
abdominal volume including the gastric bed and nodal regions (including the celiac 
axis, peri pancreatic, heptic and splenic hilum, and para aortic) ( Fig. 2). 
 
The IORT target vo lume was encompassed with a single-field using circular cones and 
bevelled ends (Fig. 3). The range of electron energies available was from 6 MeV to 20 
MeV. The external irradiation was delivered to all patients using 15 MV photon beams, 
AP-PA fields. The fields were shaped with appropriate shielding blocks to confine the 
radiation beam to the desired anatomic area. The target vo lume encompassed the areas 
considered at risk or known to have residual disease. The IORT program in our 
institution requires the transport of the patient from the surgical theatre to the room 
containing the linear accelerator. This means regularly the addition of 50-60 min. to the 
surgical time. Transportation time does not usually exceed 7 min (each way). 
 
Among the 48 patients evaluable in the trial, the age range from 34 to 76 years old 
(median 58 years). There were 35 males and 13 females. Karnofsky performance status 
was equal or superior to 70% in 37 patients (77%). The main complaint was abdominal 
pain in 25 patients at the time of diagnosis (Table 1). All tumors were reported as 
adenocarcinoma except two cases of anaplastic histologies. In 31, the subtype was either 
poorly differentiated and/or diffuse (65%). The most frequent tumor site involvement 
within the stomach was distal (involving the antropyloric area or more zones, in 22 
cases, 46%). Seven patients had an anastomotic recurrence in the stump of the previous 
gastrectomy (four gastric cancer and three benign ulcers). Four patients were 
approached with surgery, IORT, and external irradiation because of nodal recurrences in 
the celiac axis area following a previous gastrectomy. In 27 pathology specimens, nodal 
metastasis were observed. The number of nodes studied ranged from 2 to 53 with a 
median of 12 nodes per specimen. The number of tumor involved nodes ranged from 1 
to 29 with a median of three metastatic nodes. In the uninvolved nodal group, the total 
number of nodes studied ranged from 4 to 26 with a median of 10 free of malignant 
disease ( Table 2 ). 
 
The tumor extension through the gastric wall was available in 44 specimens studied 
(four patients were treated for nodal recurrences while free of mucosal or anastomotic 
relapse). In 31 cases, the tumor involved the serosa and in the remaining 13, the tumor 
did not extend further than the muscularis propia. The resection limits of gastrectomy 
along the digestive tube were microscopically involved in seven patients: five the 
esophageal and two the duodenal border. In 13 patients, components of extra gastric 
malignant disease were identified. Following the recent modification of the staging 
system for gastric cancer (33), the tumor stages were stratified as follows: 16 Stage I-II, 
19 Stage III, and 13 Stage IV. In 18 patients, the presence of two poor prognostic 
features was associated (metastatic nodes plus serosal involvement). 
 
Technical treatment aspects are summarized in Table 3. The surgical procedure 
consisted in total gastrectomy in 36 cases, partial in eight and exposure to the IORT 
beam of a nodal recurrence (without resection) in four cases. The IORT technique 
required the use of a single field in 47 procedures. The exception was one case in which 
two IORT fields were used in a large tumor involving the fundus and approached 
through a thoraco phreno-laparotomy: the fields encompassed the gastric bed and celiac 
axis in two different but adjacent volumes. The cone size employed ranged from 5 to 10 
cm in external diameter (the cone wall thickness is 3 mm). The most frequent cone size 
used was 8 cm. The electron energies selected have been in the lower spectrum 
available (6 and 9 MeV) in patients with assumed microscopic residual disease. The 
higher energies were selected in the cases with known macroscopic residual disease 
(including all cases with nodal relapses in the celiac axis area). Minor variations in the 
IORT dose delivered were accepted in the trial. The exceptions were three cases with 
suspected early tumor stages treated with 10 Gy IORT and one case of massive 
recurrence in the celiac axis with 20 Gy. In five patients with early tumor stages 
external irradiation was omitted. In the remaining 43 patients receiving external beam 
radiotherapy four had this treatment component preoperatively and 39 postoperatively 
following tumor resection or exposure of recurrences to IORT. The four patients treated 
with preoperative radiotherapy had primary tumors which were considered technically 
unresectable in a prior laparotomy. In all four cases, the external irradiation was 
administered with simultaneous chemotherapy (carboplatin 55 mg / m2 iv and 5 
fluorouracil 1000 mg/ m2 iv in 24 hr continuous infussion with a maximum of 1500 mg/ 
day on days 1-3 and 20-22 of irradiation). 
 
Chemotherapy was administered to 13 patients in this trial. Four simultaneously with 
external preoperative radiotherapy for unresectable locally advanced primary tumors. 
Three additional patients received systemic neoadjuvant chemotherapy for primary 
locally advanced (cisplatin 20 mg/ m2 iv and 5-fluorouracil 1000 mg/ m2 iv continuous 
infusion with a maximum of 1500 mg/ day on days 1 to 5 repeated every 28 days for 2 
to 4 cycles). 
 
All patients treated preoperatively were resected at the time of surgical evaluation. Ten 
patients with poor prognostic features (residual disease following gastrectomy, 
extensive nodal involvement, diffuse undifferentiated subtypes or a combination of 
these) were treated with adjuvant chemotherapy using platinum compounds and iv 
infusion of 5-fluorouracil for 4 to 6 courses, or until disease progression. ( Table 3 ) 
 
Patients were followed every 3 months in outpatient consultation. Routine blood tests 
and physical examination were performed. CT scans of the abdomen were done twice a 
year or when symptoms appear. Episodes of gastrointestinal bleeding were urgently 
studied through endoscopy and selective abdominal arteriography. Patients developing 
progressive malignant disease were studied to establish the patterns of recurrence. 
Autopsy studies were requested in eight patients dying in the hospital: five necropsies 
were performed. Survival curves are calculated using the corrections of the actuarial 
method. 
  
 
 
RESULTS 
 
Toxicity and complications  
 
In the immediate postoperative period, there were several complications observed, but 
no postoperative mortality. The morbidity consisted in five infections requiring specific 
treatment (five pneumonias and three abdominal abscess), one case of pulmonary 
emboli, three pancreatic fistula, (one distal pancreatectomy and one Whipple resection), 
one gastrointestinal bleeding and one suture dehiscence requiring reoperation. 
 
In the late follow-up period (more than 3 months from surgery) several normal tissue 
changes were observed and will be described in detail. Vertebral collapse was observed 
in six patients, involving Ll, L2, or T12 vertebral bodies. The finding was asymptomatic 
in three patients and four required anti- inflammatory oral therapy, one an orthopedic 
device and one was treated with surgical stabilization. In four patients, hypodense 
lesions developed in the liver and specific studies with isotopic labelled erythrocytes 
suggested the diagnosis of hemangiomas. Three patients required esophageal dilatations 
because of symptomatic stenosis of the area of mechanic esophagojejunal suture. One 
episode of liver infarction (in a terminal patient) and one of cholangitis were observed. 
The most relevant toxicity and complication observed was enteritis. This was defined in 
the present trial as any evidence of digestive alteration in the follow-up period, 
including persistent abdominal pain or discomfort, malabsorption, food- intake 
intolerance, together with evidence of radiologic changes compatible with intestinal 
wall and/ or mucosal edema, or areas of bowel stenosis. Enteritis was identified as 
symptomatic in nine patients (four had been treated with chemotherapy). Two of the 
nine patients required reoperations: one due to subocclusive digestive crisis and another 
from bowell wall perforation. One patient is alive with no evidence of disease at 26 
months follow-up. Five enteritis were associated with gastrointestinal bleeding. Three 
patients were diagnosed through emergency arteriography of arterioenteric fistulas and 
were reoperated. In these patients the origin of the bleeding was the left gastric artery 
stump. The time from the first surgery to reoperation from this complication was 3, 7 
and 12 months. One patient who underwent reoperation is now alive with liver 
metastasis at 22 months follow-up. The remaining two patients died in the postoperative 
period with uncontrolled intrabdominal complications. 
 
In five patients, the liver function test were altered in the follow-up period, showing 
increased values of liver enzymes. This finding was of minor clinical significance 
(Table 4). 
 
 
Patterns of tumor progression 
 
The initial site of tumor progression has been deter-mined in 18 patients with persistent 
or recurrent gastric adenocarcinoma. Intra-abdominal structures were involved in 16 
cases and extra-abdominal in four cases. Two patients had a mixed recurrent pattern. Ali 
patients, with recurrent disease in the celiac axis had macroscopic or unresected tumor 
in the area. Peritoneal seeding and ascites were identified in seven patients (two as 
mixed failure with simultaneous bone and lung metastasis). Four patients have 
developed liver metastasis. Tumor recurrence has been seen in a large portion in 
advanced tumor stages (III and IV) and undifferentiated histologic subtypes (Table 5). 
No locoregional failures were seen in patients treated with primary disease. 
  
 
Patient outcome and survival data 
 
The follow-up time of the series ranges from 4 + 76 + months with a median of 22 
months. At the time of this analysis, 22 patients are alive and free of disease, two are 
alive with disease, sixteen have died with locally recurrent or metastatic cancer and 
eight have died of intercurrent causes. Intercurrent causes of death were: cerebellar 
hematoma (at necropsy) in one patient, massive gastrointestinal bleeding in four 
patients (two were re-operated and apparently free of abdominal tumor, and in two no 
precise diagnosis was made ). 
 
Patients treated in the study protocol time period of 71 months, have an overall acturial 
survival rate projected at maximum follow-up time, of 39% (Fig. 4). A subset analysis 
by prognostic features shows survival rates for patients with positive or negative nodal 
involvement, the projected survival rates are 33% and 56%, respectively (Fig. 5). The 
combination of the worst prognostic features, that of serosal and nodal involvement, 
shows an actuarial survival rate of 26%. In calculating these figures, the patients with 
recurrent nodal disease in the celiac axis were excluded. There are two long-term 
surviving patients (22+ and 65+ months) free of detectable disease with known residual 
tumor after maximal resection. 
 
 
DISCUSSION 
 
The tolerance of upper abdominal organs and structures to external beam radiotherapy 
following gastric resection have been tested in some clinical trials reported previously 
(6, 10, 24, 35, 41). Few events were described as major toxicities supposedly induced 
by radiotherapy, which implies that an acceptable clinical tolerance might be assumed 
from those trials, if the technical aspects involved in delivering the treatment are 
followed meticulously. 
  
The information with regards to tolerance of normal tissues in clinical trials using IORT 
in gastric cancer patients is disperse and inconsistent (10, 17, 20, 25, 29, 36). The IORT 
technique varied the different trials which impose to be cautious at the time of 
comparing the end results. In several studies IORT has been used as the only 
radiotherapy component of the treatment program, but administering a large single 
fraction in the range of 28 to 35 Gy. In this type of approach slight elevations of the 
serum amylase and insulin levels were described, with later normalization of these 
values (4). Other isolated treatment induced changes were gastric ulcer and 
gastrointestinal bleeding reported by the same group of investigators (27). It is uncertain 
as to whether the stomach or small intestine were included in the IORT field. Data from 
another trial using IORT as the only radiotherapy treatment component in one study are 
was reported by the NCI group using 25 Gy following gastrectomy but delivered in the 
upper abdominal structures through a multiple field adjacent fields technique (42). The 
study was closed with few patients in the IORT arm (10 cases), but some toxic episodes 
were reported among this small group, including cases of gastrointestinal bleeding (32, 
43). There is no yet information available from a comparable clinical trial to the 
experience reviewed in this report: a moderate intraoperative single dose of radiation 
using an electron beam (15 Gy), plus a large external beam volume treated 
conventionally to 46 Gy, as an in-tense treatment program following gastrectomy in 
gastric cancer patients. Large animal models have tested the tolerance of normal tissues 
to increasing doses of EBRT alone, IORT alone, or the combination of EBRT (50 Gy) 
and increasing doses of IORT (18, 34). With treatment combinations in the range of 
IORT (15 Gy) plus EBRT (46-50 Gy) the pancreas (5) large vessels (19) and bone (39) 
were structures that showed an acute and long-term acceptable tolerance in the dog 
model. In the clinical setting, the treatment program has proven to be feasible but 
associated to occasionally severe complications (8, 13, 26, 40, 41). Gastrointestinal 
bleeding was observed in five instances, in which an arterioenteric fistula was 
documented in three cases. The pathogenesis of this event is not completely clear. A 
suggested theoretical explanation for the finding is the development of enteritis, bowel 
wall perforation, secondary intra-abdominal infection that might induce an arterial wall 
erosion and a subsequent fistula (14). In the present experience a case, in which a 
pseudoaneurysmatic change was observed in the left gastric artery stump, developed a 
fistula that can be attributed in pan to the IORT component of the treatment. In the 
present trial, the small bowel was never included in the IORT field, but the arterial 
vessels of the upper abdomen including the coeliac trunk, superior mesenteric artery and 
a portion of the aorta were always included in the target volume of IORT. Other 
aneurysmatic and/or stenotic changes were not detected in any case followed for more 
than 2 years after treatment. The routine CT scans performed could not show 
morphologic changes in these structures. The gastrointestinal bleeding episodes 
observed in this trial were not fully explainable on the basis of the treatment intensity 
employed and this was not a universal finding. Severe gastrointestinal bleeding was 
observed only in patients with associated enteritis. Other observations that might be 
interpreted as side effects from the treatment program have been vertebral collapse and 
liver enzymes elevations. Vertebral collapse has been described in previous reports 
using IORT in para-aortic spaces (40). The complication was symptomatic in all 
patients but improved with time, and pain was controlled by anti- inflammatory therapy. 
Two patients required temporary use of a cast. The rest of the mentioned treatment 
complications were not severe in character and tend to improve or stabilize with time. In 
five cases, liver hemangiomas simulated liver metastasis. Nevertheless, the possible 
relationship between the development of hemangiomas as treatment related 
complications is at the present moment unexplainable. Patients with liver enzymes 
elevated values had simultaneous symptoms of enteritis. 
 
Nine patients required reoperations in the follow-up period: 6 due to related 
complications, one to tumor progression and two to unrelated processes to their disease 
and/ or treatment. One patient survived 22 months following an emergency laparotomy 
for arterio-enteric fistula with no further bleeding. All patients requiring surgical 
procedures for benign processes or non-treatment related complications recovered 
without morbidity. 
 
The patterns of tumor recurrence are particularly difficult to assess in post-resected 
gastric cancer patients. Landry et al. (30) recently reported that 38% of all initial sites of 
disease recurrence occur in intra-abdominal structures. In most cases, tumor progression 
was noted to involve multiple concurrent zones within the abdomen. In our experience, 
local recurrence was confined to patients with unresectable disease in the celiac axis. 
Sites of failure included unresectable nodal area in the celiac axis (3 out of 4 cases) and 
mucosal anastomosis (one case). Seven cases of peritoneal seeding were detected in 
patients with poor prognostic features. Extra-abdominal recurrence was a rare clinical 
finding. A compared discussion with previous adjuvant gastric cancer trials is limited by 
the lack of detailed analysis of locoregional pattern of progression. 
 
The analysis of survival is a particular delicate aspect in this type of trials. The overall 
survival of the group is projected for the entire group to the maximum follow-up (76 
months) as 39%. In eight patients, the cause of death was not tumor recurrence. Survival 
values tends to be related to pathologic prognostic features: positive or negative serosal 
involvement (33% vs. 66%, respectively), the presence or absence of nodal metastasis 
(33% vs. 56%, respectively) and postsurgical tumor residual (18% for macroscopic 
residual disease vs 69% with microscopic residual). Any intent to compare the present 
data with previous clinical reports using IORT in gastric cancer patients will have 
important methological objections. The tumor staging classification has changed in the 
last decade, re-grouping patients with different pathologic features, and asking for 
certain information that will not longer be available from past analysis and even in most 
contemporary studies, such as the measurement of the distance between the primary 
tumor and the metastatic nodes (9 ). This will compromise our ability to compare recent 
and future survival figures with historical data. Nevertheless, it is important to remark 
that there are long-term surviving patients with a combination of poor prognostic 
features including one recurrent case with post-surgical macroscopic residual disease (7, 
45) 
 
In summary, the combination of gastrectomy, single field of intraoperative radiotherapy 
delivering a moderate single dose (15 Gy) to the upper abdominal central axis nodes, 
followed by a full course of externa l beam irradia tion (46 Gy in 23 fractions, 2 Gy per 
fraction) to a large field encompassing the upper abdominal nodal regions and the 
gastric bed, is a feasible treatment approach (11). The clinical observations appears to 
reach the tolerance limit of the treatment intensification in this particular anatomic area. 
The locoregional tumor control rates are high, with no failures in patients treated for 
primary disease, which allows one to recommend a certain compromise to decrease the 
total radiation dose delivered by both treatment component s, IORT and EBRT. 
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Figure 1. View of the IORT target field through the cone. Notice the left gastric artery 
stump in the right upper comer of the image. 
 
 
 
 
Figure 2. Diagram of the integration of IORT plus externa l beam irradiation volume. 
 
 
 
Figure 3. IORT cone positioned. Notice that the upper abdominal mobile structures are 
retracted from the treatment field. 
 
 
 
 
Figure 4. Overall actuarial survival curve for the entire group of gastric cancer patients 
treated with IORT. 
 
 
 
 
Figure 5. Comparative actuarial survival curves regarding presence or absence of 
serosal involvement. Patients with recurrent nodal masses are excluded from this 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Patients characteristic 
Patients No. % 
Total number 48 100 
Age (years)   
Range 34-76  
Median 58  
Sex   
Male 35 73 
Female 13 27 
Karnofsky   
< 70% 11 23 
> 70% 37 77 
Symptoms   
Pain 25 52 
Weight Loss 10 21 
GI bleeding 7 14 
Vomiting 6 12 
Dysphagia 5 10 
Anemia 4 8 
 
  
Table 2. Tumor characteristics 
Tumor No. % 
Histology   
Adenocarcinoma 46 96 
Well/moderately differentiated 15 31 
Poorly differentiated/diffuse 31 65 
Other 2 4 
Location   
Proximal (cardias-fornix) 6 13 
Central (corpus) 5 10 
Distal (antrum-pilorum) 19 40 
Anastomotic site (stump) 7 15 
Celiac axis relapse 4 8 
Proximal + central 4 8 
Central + distal 2 4 
Proximal + central + distal 1 2 
Nodes   
Positive 27 56 
Negative 21 44 
Serosa   
Involved 31 70 
Uninvolved 13 30 
Stage   
I-I 16 33 
III 19 40 
IV 13 27 
Table 3. Treatment characteristics 
Treatment No. % 
Surgery   
Total gastrectomy 36 7 
Partial gastrectomy 8 17 
Tumor exposure 4 8 
IORT   
Cone size   
5-6 cm 8 17 
7-8 cm 25 52 
9-10 cm 17 35 
Number of fields   
Single 47 98 
Multiple 1 2 
Electron energy   
6-9 Mev 18 37 
12-15 MeV 27 56 
18-20 MeV 5 10 
Total dose   
10 Gy 3 6 
15 Gy 46 96 
20 Gy 1 2 
External beam RT   
Preoperative 4 8 
Postoperative 39 81 
Not given 5 11 
Chemotherapy 13 27 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Toxicity and complications 
Observations No. % 
Acute   
Pneumonia 5 10 
Suture dehiscence 1 2 
Abdominal-pulmonary/abcess 5 10 
Gastrointestinal bleeding 1 2 
Sepsis 1 2 
Pulmonary emboli 1 2 
Pancreatic fistula 3 6 
Late   
Vertebral collapse 6 12 
Esophageal dilatations 3 6 
Liver infarction 1 2 
Cholangitis 1 2 
Fistula 3 6 
Enteritis 9 19 
Gastrointestinal bleeding 5 10 
Liver function test altered 5 10 
Reoperations (laparotomies)* 9 19 
* Six treatment related. 
 
 
 
 
Table 5. Patterns of disease progression 
 Site of progression 
 Intra-abdominal Extra-abdominal 
Tumor factors  CA P Li N LU B 
Stage       
I-II -  -  1 -  1 -  
III 2 5 1 1 -  -  
IV 3 2 2 1 -  1 
Histology       
Well/moderately differentiated 2 2 -  -  1 -  
Undifferentiated 3 5 4 2 -  1 
No. patients (18) 5 7 4 2 1 1 
CA = Celiac axis; P = Peritoneum; Li = Liver; N = Nodes; B = Bone; Lu = Lung 
 
